Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) FCF Margin (2020 - 2025)

Historic FCF Margin for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to 43.42%.

  • Maravai Lifesciences Holdings' FCF Margin fell 500100.0% to 43.42% in Q3 2025 from the same period last year, while for Sep 2025 it was 34.47%, marking a year-over-year decrease of 306000.0%. This contributed to the annual value of 8.56% for FY2024, which is 295600.0% down from last year.
  • As of Q3 2025, Maravai Lifesciences Holdings' FCF Margin stood at 43.42%, which was down 500100.0% from 27.72% recorded in Q2 2025.
  • Maravai Lifesciences Holdings' FCF Margin's 5-year high stood at 97.7% during Q1 2023, with a 5-year trough of 43.42% in Q3 2025.
  • Moreover, its 5-year median value for FCF Margin was 11.35% (2024), whereas its average is 17.67%.
  • In the last 5 years, Maravai Lifesciences Holdings' FCF Margin soared by 558700bps in 2021 and then tumbled by -1197200bps in 2024.
  • Quarter analysis of 5 years shows Maravai Lifesciences Holdings' FCF Margin stood at 23.24% in 2021, then soared by 96bps to 45.49% in 2022, then crashed by -127bps to 12.15% in 2023, then tumbled by -198bps to 36.22% in 2024, then fell by -20bps to 43.42% in 2025.
  • Its FCF Margin was 43.42% in Q3 2025, compared to 27.72% in Q2 2025 and 31.22% in Q1 2025.